Compare SCOR & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCOR | ACOG |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.4M | 110.4M |
| IPO Year | 2007 | N/A |
| Metric | SCOR | ACOG |
|---|---|---|
| Price | $7.31 | $6.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 12.7K | ★ 41.7K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.37 | N/A |
| EPS | ★ 4.25 | N/A |
| Revenue | ★ $403,549,000.00 | N/A |
| Revenue This Year | $2.75 | $139.22 |
| Revenue Next Year | $7.30 | $134.48 |
| P/E Ratio | $1.73 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $4.39 | $4.50 |
| 52 Week High | $10.18 | $10.88 |
| Indicator | SCOR | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 50.30 |
| Support Level | $6.28 | $5.00 |
| Resistance Level | $7.18 | $6.59 |
| Average True Range (ATR) | 0.54 | 0.42 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 16.35 | 40.21 |
comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.